International Journal of Cardiology Cardiovascular Risk and Prevention最新文献

{"title":"The association between cognitive function trajectories and all-cause mortality in middle-aged and older Chinese adults with cardiovascular disease: A longitudinal study from CHARLS","authors":"Xiaopeng Song ,&nbsp;Yufei Wang ,&nbsp;Hua Chen","doi":"10.1016/j.ijcrp.2026.200583","DOIUrl":"10.1016/j.ijcrp.2026.200583","url":null,"abstract":"<div><h3>Objective</h3><div>To identify distinct multi-year cognitive function trajectories in middle-aged and older Chinese adults with established cardiovascular disease (CVD) and evaluate their independent associations with all-cause mortality.</div></div><div><h3>Methods</h3><div>This prospective study utilized data from five waves (2011–2020) of the China Health and Retirement Longitudinal Study (CHARLS). A total of 1464 participants aged ≥45 years with CVD were included. Global cognitive scores (range 0–21) were assessed at three time points (2011, 2013, and 2015). A Longitudinal K-means clustering algorithm with Dynamic Time Warping was employed to identify cognitive trajectories. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for all-cause mortality during a mean follow-up of 4.7 years.</div></div><div><h3>Results</h3><div>Four distinct cognitive trajectories were identified: High-Baseline-Relatively-Stable (39.1 %), Mid-High-Baseline-Significant-Improvement (31.2 %), Mid-Baseline-Rapid-Decline (16.7 %), and Low-Baseline-Relatively-Stable (13.0 %). Using the Mid-High-Baseline-Significant-Improvement group as the reference, both the Mid-Baseline-Rapid-Decline trajectory (adjusted HR = 2.01; 95 % CI: 1.32–3.05) and the Low-Baseline-Relatively-Stable trajectory (adjusted HR = 1.82; 95 % CI: 1.10–3.00) were significantly associated with an increased risk of all-cause mortality after adjusting for covariates. The association was notably stronger among participants with hypertension (P for interaction = 0.009).</div></div><div><h3>Conclusions</h3><div>Among middle-aged and older adults with CVD, trajectories characterized by rapid cognitive decline or persistently low function are powerful, independent predictors of all-cause mortality. In contrast, cognitive improvement is not associated with excess mortality risk. These findings underscore the prognostic importance of dynamic cognitive assessment and suggest that monitoring cognitive trajectories may aid in the risk stratification of CVD patients.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200583"},"PeriodicalIF":2.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal and cardiovascular effects of SGLT2 inhibitors among hypertensive patients with chronic kidney disease: A systematic review and meta-analysis","authors":"R. Mohamad Javier ,&nbsp;Iqbal Faizin ,&nbsp;Andiani ,&nbsp;Dian Samudra ,&nbsp;Renny Anggraeni Puspitasari ,&nbsp;Ahmad Surya Dharma ,&nbsp;Brianka Yudha Nurpradika ,&nbsp;Fauqi Amalia ,&nbsp;Siska Suridanda Danny ,&nbsp;Brm Ario Suryo Kuncoro ,&nbsp;Yusra Pintaningrum ,&nbsp;Muhammad Almy Firasghani ,&nbsp;Puput Fiohana ,&nbsp;Yosua Darmadi Kosen ,&nbsp;Kristian Kurniawan","doi":"10.1016/j.ijcrp.2026.200585","DOIUrl":"10.1016/j.ijcrp.2026.200585","url":null,"abstract":"<div><h3>Background</h3><div>Chronic kidney disease (CKD) is frequently complicated by hypertension, a dual contributor to disease progression and cardiovascular risk. Despite standard therapy with renin–angiotensin–aldosterone system inhibitors, residual risk remains high. Sodium–glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapy with proven renal and cardiovascular benefits, but their effects in hypertensive CKD patients remain less well defined.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that evaluated SGLT2 inhibitors in CKD patients with baseline systolic blood pressure ≥140 mmHg or renovascular disease. PubMed, Embase, and Cochrane Library were searched from inception to August 2024. Eligible RCTs compared an SGLT2 inhibitor versus placebo and reported outcomes in hypertensive subgroups. Primary outcome was a composite of kidney failure, sustained decline in estimated glomerular filtration rate (eGFR ≥40–50 %), or cardiovascular death. Secondary outcomes included kidney-specific endpoints, cardiovascular composite outcomes, and serious adverse events (SAEs). Pooled odds ratios (ORs) were calculated using random-effects models.</div></div><div><h3>Results</h3><div>Three RCTs were included: CREDENCE (canagliflozin), DAPA-CKD (dapagliflozin), and EMPA-KIDNEY (empagliflozin), encompassing 5436 hypertensive participants. For the primary outcome, SGLT2 inhibitors reduced risk compared with placebo (OR 0.76, 95 % CI 0.65–0.88). Kidney outcomes showed consistent benefit (OR 0.70, 95 % CI 0.58–0.85). Cardiovascular events were modestly reduced (OR 0.79, 95 % CI 0.64–0.97). SAEs were slightly lower with SGLT2 inhibitors (OR 0.85, 95 % CI 0.74–0.96). Overall certainty of evidence was graded as moderate.</div></div><div><h3>Conclusions</h3><div>Among hypertensive patients with CKD, SGLT2 inhibitors significantly reduce renal disease progression and cardiovascular events while maintaining favorable safety. These findings support their integration into standard therapy for this high-risk population.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200585"},"PeriodicalIF":2.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146191294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Trends in coronary artery disease mortality among hyperlipidemic patients: Geographic, gender, and racial insights from CDC WONDER data (1999–2020)","authors":"Mohamed Fawzi Hemida MD","doi":"10.1016/j.ijcrp.2026.200581","DOIUrl":"10.1016/j.ijcrp.2026.200581","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200581"},"PeriodicalIF":2.1,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of COVID-19 pandemic on admission, management and mortality of pulmonary embolism in cancer patients","authors":"Dror Magen ,&nbsp;Adam Folman ,&nbsp;Marlon V. Gatuz ,&nbsp;Rami Abu Fanne ,&nbsp;Ariel Roguin ,&nbsp;Ofer Kobo","doi":"10.1016/j.ijcrp.2026.200580","DOIUrl":"10.1016/j.ijcrp.2026.200580","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary embolism (PE) is a leading cause of morbidity among cancer patients. The COVID-19 pandemic introduced new challenges to healthcare delivery. This study aimed to evaluate the impact of the COVID-19 pandemic on PE-related hospitalizations, treatment, and in-hospital outcomes in patients with active cancer.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis using the National Inpatient Sample database from 2016 to 2021. Patients with active cancer and a primary diagnosis of acute PE were categorized into three groups: pre-COVID-19 (2016–2019), peak COVID-19 (2020), and ongoing COVID-19 (2021). We compared baseline characteristics, in-hospital procedures, and clinical outcomes among these groups. Multivariable logistic regression was employed to assess associations between COVID-19 periods and outcomes.</div></div><div><h3>Results</h3><div>Among 170,630 patients with PE and cancer, admission rates decreased during the pandemic. Patients hospitalized during the COVID-19 pandemic more frequently presented with severe PE phenotypes, including saddle PE (9.7 % and 9.4 % vs. 7.5 %, p &lt; 0.001) and acute cor pulmonale (8.4 % and 8.9 % vs. 5.9 %, p &lt; 0.001). Thrombolysis-based therapies increased during the pandemic, whereas adjusted odds of catheter-directed embolectomy were lower. Despite more severe presentations, in-hospital mortality remained relatively stable (6.0 % pre-COVID-19, 6.0 % peak, 5.5 % ongoing; p = 0.004).</div></div><div><h3>Conclusion</h3><div>The COVID-19 pandemic led to decreased PE-related hospitalizations among cancer patients but was associated with more severe presentations and shifts in therapeutic strategies. Notably, in-hospital mortality remained stable, which may be consistent with maintained PE care pathways during the pandemic. These findings highlight the need for robust, adaptable healthcare systems to ensure continuity of care for high-risk populations during global health crises.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200580"},"PeriodicalIF":2.1,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extent and predictors of guideline-directed medical therapy optimization during cardiac rehabilitation in patients with heart failure","authors":"Corentin Nicolas ,&nbsp;Nicolas Girerd ,&nbsp;Kevin Duarte ,&nbsp;Olivier Huttin ,&nbsp;Karim Djaballah ,&nbsp;Jerome Felloni ,&nbsp;Guillaume Baudry ,&nbsp;Luca Monzo","doi":"10.1016/j.ijcrp.2026.200579","DOIUrl":"10.1016/j.ijcrp.2026.200579","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac rehabilitation (CR) may offer a structured framework for guideline-directed medical therapy (GDMT) optimization, but its real-world impact is uncertain. We aimed to quantify GDMT optimization and identify its clinical predictors during CR.</div></div><div><h3>Methods</h3><div>This retrospective single-centre study included patients hospitalized for acute HF with reduced (HFrEF) or mildly reduced (HFmrEF) ejection fraction who subsequently underwent first inpatient or ambulatory CR at Nancy University Hospital (2021–2024). Changes in GDMT optimization were evaluated using the HF prescription and the KCMO scores and expressed as adjusted standardized differences (ASD). Multivariable linear regression identified independent predictors of optimization.</div></div><div><h3>Results</h3><div>Among the 106 patients included (84 % HFrEF, mean age 59 years; 75 % male), baseline GDMT use was high, but doses were suboptimal. During CR, significant uptitration occurred across all major drug classes, including angiotensin receptor–neprilysin inhibitors (ASD: +22 %), beta-blockers (ASD: +21 %), mineralocorticoid receptor antagonists (ASD: +43 %), and sodium–glucose cotransporter 2 inhibitors (ASD: +45 %) (all p &lt; 0.001). Overall GDMT optimization improved significantly, as evidenced by increases in both the KCMO (ASD: +39.9) and HF prescription (ASD: +1.27) scores (both p &lt; 0.001), with consistent effects across inpatient and ambulatory settings. In multivariable analysis, higher loop-diuretic dose and prior treatment by HF specialists were associated with less optimization, whereas hypertension predicted greater intensification.</div></div><div><h3>Conclusions</h3><div>Cardiac rehabilitation after HF hospitalization promoted substantial GDMT optimization, especially in hypertensive patients. Higher loop-diuretic dose at admission predicted less optimization, suggesting that minimizing diuretic doses may ease GDMT titration.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200579"},"PeriodicalIF":2.1,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine therapy in transcatheter aortic valve replacement: Modulating inflammation and outcomes","authors":"Hamza A. Abdul-Hafez ,&nbsp;Ameer Awashra ,&nbsp;Malik Ahmad ,&nbsp;Abdullah Raed Hawawrah ,&nbsp;Bayan Mahafdah ,&nbsp;Mohammed AbuBaha ,&nbsp;Ibrahim Alazizi ,&nbsp;Abdalhakim Shubietah ,&nbsp;Mohamed S. Elgendy ,&nbsp;Ahmed Emara","doi":"10.1016/j.ijcrp.2026.200575","DOIUrl":"10.1016/j.ijcrp.2026.200575","url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter aortic valve replacement (TAVR) is frequently accompanied by inflammation-related complications, including conduction disturbances, atrial fibrillation, and subclinical leaflet thrombosis. Colchicine, with its anti-inflammatory and antithrombotic properties, has emerged as a potential adjunctive therapy to mitigate these post-procedural events. However, its specific role in the TAVR population remains insufficiently defined.</div></div><div><h3>Methods</h3><div>A narrative review approach was used. Searches of PubMed, Scopus, Web of Science, and Google Scholar were performed through September 2025 using terms related to “transcatheter aortic valve replacement,” “TAVR,” and “colchicine.” Randomized trials, observational studies, mechanistic investigations, and guideline documents were screened. Findings were organized thematically to summarize mechanisms, therapeutic rationale, and clinical outcomes.</div></div><div><h3>Results</h3><div>Only one randomized controlled trial and one observational study have directly evaluated colchicine after TAVR. Both demonstrated reductions in inflammatory biomarkers and signals toward improved conduction-related parameters, but clinical endpoints such as pacemaker implantation, sustained arrhythmias, and imaging-confirmed leaflet thrombosis remain insufficiently studied. Mechanistic and perioperative cardiac evidence from non-TAVR settings supports colchicine’s potential by targeting inflammasome activity, microtubule regulation, and early thrombo-inflammatory remodeling.</div></div><div><h3>Conclusions</h3><div>Colchicine is a promising adjunctive strategy for attenuating inflammation-related complications after TAVR. Its multimodal actions align with the pathways implicated in conduction disturbances, atrial fibrillation, and leaflet thrombosis. However, current evidence is preliminary, with only two post-TAVR intervention studies available. Larger trials are needed to determine whether colchicine can translate mechanistic advantages into clinically meaningful improvements in post-TAVR outcomes.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200575"},"PeriodicalIF":2.1,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on: “Association between body roundness index trajectories and the risk of cardiometabolic multimorbidity in Chinese middle-aged and older adults: Evidence from the China health and retirement longitudinal study”","authors":"Bin Cao ,&nbsp;Bingning Ma","doi":"10.1016/j.ijcrp.2026.200578","DOIUrl":"10.1016/j.ijcrp.2026.200578","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200578"},"PeriodicalIF":2.1,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of an assessment form on promoting in-hospital initiation of sodium–glucose cotransporter-2 inhibitors in hospitalized patients with heart failure","authors":"Takuya Okamoto ,&nbsp;Koichiro Matsumura ,&nbsp;Hiroyo Miyata ,&nbsp;Yuta Kimoto ,&nbsp;Kazue Hamamura ,&nbsp;Keiko Kato ,&nbsp;Shohei Hakozaki ,&nbsp;Eijiro Yagi ,&nbsp;Masafumi Ueno ,&nbsp;Kimiko Fujiwara ,&nbsp;Manabu Takegami ,&nbsp;Gaku Nakazawa","doi":"10.1016/j.ijcrp.2026.200577","DOIUrl":"10.1016/j.ijcrp.2026.200577","url":null,"abstract":"<div><h3>Background</h3><div>Despite the established benefits of in-hospital administration of sodium–glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure (HF), their implementation remains insufficient. To investigate whether the use of an Assessment Form influences SGLT2i prescriptions at discharge among hospitalized patients with HF.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed consecutive patients with HF from a prospective registry between September 2024 and August 2025 after the implementation of an Assessment Form. Patients who died during hospitalization were excluded. The Assessment Form was completed collaboratively by physicians and nurses. Physicians checked whether guideline-directed medical therapy (including SGLT2i) had been prescribed, and documented the reasons if not initiated, while nurses evaluated the patients’ pre-hospital living conditions and self-care abilities. The primary endpoint was the prescription rate of SGLT2i at discharge according to the Assessment Form.</div></div><div><h3>Results</h3><div>Among the 208 analyzed patients (median age, 81 years [range, 75–87] years, 59 % male], the Assessment Form was used by 61.1 % (127/208). The prescription rate of SGLT2i at discharge was significantly higher in patients who completed the Assessment Form than in those who did not (65.4 % vs. 45.7 %, <em>p</em> &lt; 0.01). Multivariable logistic regression identified use of the Assessment Form as an independent factor associated with SGLT2i prescription at discharge (odds ratio 2.12, 95 % confidence interval 1.04–4.32, <em>p</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>Implementation of an Assessment Form was associated with increased initiation of in-hospital SGLT2i therapy. The active use of such structured forms may help promote adherence to guideline-directed therapies during hospitalization for HF.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200577"},"PeriodicalIF":2.1,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk for coronary artery disease among individuals with normal low-density lipoprotein cholesterol (LDL-C) levels","authors":"Zhuqing Shi ,&nbsp;Ashley J. Mulford ,&nbsp;Jun Wei ,&nbsp;Huy Tran ,&nbsp;Annabelle Ashworth ,&nbsp;S. Lilly Zheng ,&nbsp;Brian T. Helfand ,&nbsp;David Duggan ,&nbsp;Henry M. Dunnenberger ,&nbsp;Peter J. Hulick ,&nbsp;David J. Davidson ,&nbsp;Arman Qamar ,&nbsp;Alan R. Sanders ,&nbsp;Jianfeng Xu","doi":"10.1016/j.ijcrp.2026.200572","DOIUrl":"10.1016/j.ijcrp.2026.200572","url":null,"abstract":"<div><h3>Background</h3><div>Low-density lipoprotein cholesterol (LDL-C) levels &lt;100 mg/dL are generally considered normal. We tested the controversial hypothesis that a subset of individuals with ‘normal’ LDL-C levels may have a non-negligible risk of coronary artery disease (CAD) due to inherited factors, including monogenic variants and polygenic risk scores (PGS).</div></div><div><h3>Methods</h3><div>A retrospective analysis of a prospective cohort from the Genomic Health Initiative at Endeavor Health, including 7880 participants without a prior diagnosis of CAD and not on statins at recruitment. Participants were stratified by baseline LDL-C levels and followed for incident CAD. The association of CAD risk with carrier status for pathogenic/likely pathogenic (P/LP) variants in <em>LDLR</em>, <em>APOB</em>, and <em>PCSK9</em>, as well as with PGS, was tested using Cox regression models adjusted for relevant covariates at baseline.</div></div><div><h3>Results</h3><div>Among participants, 31.2 % had LDL-C &lt;100 mg/dL (normal), 39.5 % had LDL-C 100–129 mg/dL, and 29.3 % had LDL-C ≥130 mg/dL. Over a median follow-up of 8 years, CAD was diagnosed in 5.3 %, 6.9 %, and 7.6 % of participants in these LDL-C groups, respectively. Among those with normal LDL-C, CAD incidence rose to 9.5 % in individuals with high genetic risk (P/LP variants and/or high PGS). Genetic risk was significantly associated with CAD in multivariable models (<em>P</em> &lt; 0.001). These findings were consistent in subjects of European and non-European ancestry.</div></div><div><h3>Conclusion</h3><div>Individuals with ‘normal’ LDL-C levels can have substantial CAD risk if they carry high genetic risk. These findings underscore the importance of incorporating genetic information into CAD risk assessment, even among those with traditionally normal lipid profiles.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200572"},"PeriodicalIF":2.1,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between nutrition status and muscle mass and its impact on 1-year mortality in patients with aortic stenosis undergoing transcatheter aortic valve implantation","authors":"Hiroyo Miyata ,&nbsp;Koichiro Matsumura ,&nbsp;Kazue Hamamura ,&nbsp;Masakazu Yasuda ,&nbsp;Shohei Hakozaki ,&nbsp;Kyohei Onishi ,&nbsp;Eijiro Yagi ,&nbsp;Kosuke Fujita ,&nbsp;Katsumi Kajihara ,&nbsp;Teruyoshi Amagai ,&nbsp;Masafumi Ueno ,&nbsp;Gaku Nakazawa","doi":"10.1016/j.ijcrp.2026.200573","DOIUrl":"10.1016/j.ijcrp.2026.200573","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to evaluate whether dual assessment of nutritional status and muscle mass could enhance the prediction of 1-year mortality in patients undergoing transcatheter aortic valve implantation (TAVI).</div></div><div><h3>Methods</h3><div>This retrospective study included 312 consecutive patients who underwent TAVI for aortic stenosis. Nutritional status was determined by calculating the geriatric nutritional risk index (GNRI), with a cutoff of 98. Muscle mass was calculated from the psoas muscle volume index (PMVI). Patients were stratified into three groups based on GNRI and PMVI: Low, middle, and high groups (GNRI: &lt; 98, &lt; 98, and &gt; 98; and below, or below, and above the sex-specific median PMVI, respectively). The primary endpoint was all-cause mortality within 1-year.</div></div><div><h3>Results</h3><div>After exclusion, 259 patients were included in the analysis, and 22 died within 1-year. Kaplan-Meier survival curves showed a significant difference in all-cause mortality within 1-year among the three groups. Multivariate analysis of the Cox proportional hazards model for factors related to all-cause mortality within 1-year showed no significant association in the middle group when the high group was used as a reference, and the low group was independently associated.</div></div><div><h3>Conclusion</h3><div>The combined assessment of nutritional status and muscle mass improves the identification of high-risk patients undergoing transcatheter aortic valve implantation and enhances the prognostic accuracy beyond individual markers. This approach may aid in refining the risk stratification and tailoring the perioperative management of patients undergoing TAVI.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200573"},"PeriodicalIF":2.1,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}